Additionally, the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab (Avastin®, Genentech; South San Francisco, CA) 7 is approved specifically for nonsquamous NSCLC because of heightened bleeding-related safety issues among patients with squamous tumors 8,9, an observation that has extended to some small molecule inhibitors, including sorafenib (Nexavar®, Bayer; Leverkusen, Germany) 10, sunitinib (SU11248, Sutent®, Pfizer; New London, CT) 11, and motesanib (Amgen; Thousand Oaks, CA) 12. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.